Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that intensive acid suppression with a long acting high potency
proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of
inflammatory mediators (compared to conventional PPIs) in the esophagus, which could
potentially lead to decreased recurrence of intestinal metaplasia following endoscopic
ablation.